Menu
Not yet recruiting NCT07028255

Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels

No phase Interventional Testosterone

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Qualia Testosterone, Placebo.
Who it may be relevant to
Registry conditions: Testosterone. Basic parameters: 28 years — 65 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels: A Randomized Double-Blind Parallel Trial

Overview

This is a randomized, double-blind, placebo-controlled parallel trial designed to assess the efficacy of Qualia Testosterone, a novel dietary supplement, in adult males aged 28 to 65 experiencing symptoms associated with testosterone deficiency. Approximately 60 participants will be randomized to receive either Qualia Testosterone (2 capsules daily) or a matched placebo for 21 days, with dosing administered each morning. The study's primary outcomes are changes in total testosterone, free testosterone (via dialysis), and dihydrotestosterone levels from baseline to Week 3. Secondary outcomes include changes in Aging Male Symptoms Scale scores-encompassing psychological, somatic, and sexual domains-as well as safety and tolerability. Blood samples will be collected in a laboratory setting, while symptom and safety assessments will be completed electronically at home.

Interventions

  • Dietary supplement Qualia Testosterone
    Qualia Testosterone manufactured by Qualia Life Sciences
  • Dietary supplement Placebo
    Rice Flour

Primary outcome measures

  • Between-group change in blood testosterone levels [Time frame: 3 weeks]
Secondary outcome measures (2)
  • Aging Male Symptoms Scale scores [Time frame: Week 3]
  • Side effect profile as measured by a custom Safety and Tolerability survey [Time frame: Week 1, 2 and 3]

Eligibility criteria

Inclusion criteria

Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.

Male participants aged 28-65 A score ≥27 on the Aging Males Symptom Scale Willing and able to visit a local blood draw facility for required blood sample collections Live within 20 miles of a suitable blood draw facility Willing to not consume any supplements containing Testosterone starting about 2 weeks prior to the baseline blood test test continuing through the intervention period.

Exclusion criteria

Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent Have Hypogonadism

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Other

Study locations

United States · 1 center
  • Qualia Life Sciences — Carlsbad

Identifiers

NCT: NCT07028255 · QLS-013

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗